Department of Public Health Sciences, University of Virginia, 560 Ray C. Hunt Dr., P.O. Box 800765, Charlottesville, VA 22903, USA.
Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1110 Fairview Avenue N, Seattle, WA 98109, USA.
Gynecol Oncol. 2018 Oct;151(1):53-60. doi: 10.1016/j.ygyno.2018.08.016. Epub 2018 Aug 16.
Major changes in the classification of ovarian carcinoma histotypes occurred over the last two decades, resulting in the current 2014 World Health Organization (WHO) diagnostic criteria that recognize five principal histotypes: high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous carcinoma. We assessed the impact of these guidelines and use of immunohistochemical (IHC) markers on classification of ovarian carcinomas in existing population-based studies.
We evaluated histotype classification for 2361 ovarian carcinomas diagnosed between 1999 and 2009 from two case-control studies using three approaches: 1. pre-2014 WHO ("historic") histotype; 2. Standardized review of pathology slides using the 2014 WHO criteria alone; and 3. An integrated IHC assessment along with the 2014 WHO criteria. We used Kappa statistics to assess agreement between approaches, and Kaplan-Meier survival curves and Cox proportional hazards models to evaluate mortality.
Compared to the standardized pathologic review histotype, agreement across approaches was high (kappa = 0.892 for historic, and 0.849 for IHC integrated histotype), but the IHC integrated histotype identified more low-grade serous carcinomas and a subset of endometrioid carcinomas that were assigned as high-grade serous (n = 25). No substantial differences in histotype-specific mortality were observed across approaches.
Our findings suggest that histotype assignment is fairly consistent regardless of classification approach, but that progressive improvements in classification accuracy for some less common histotypes are achieved with pathologic review using the 2014 WHO criteria and with IHC integration. We additionally recommend a classification scheme to fit historic data into the 2014 WHO categories to answer histotype-specific research questions.
过去二十年中,卵巢癌组织学类型的分类发生了重大变化,导致目前采用 2014 年世界卫生组织(WHO)诊断标准,该标准将五种主要组织学类型分别定义为高级别浆液性癌、低级别浆液性癌、子宫内膜样癌、透明细胞癌和黏液性癌。我们评估了这些指南的影响以及免疫组织化学(IHC)标志物在现有基于人群研究中对卵巢癌分类的作用。
我们使用三种方法评估了两个病例对照研究中 1999 年至 2009 年间诊断的 2361 例卵巢癌的组织学类型分类:1. 2014 年 WHO 分类前(“历史”)组织学类型;2. 单独使用 2014 年 WHO 标准对病理切片进行标准化复查;3. 整合 IHC 评估与 2014 年 WHO 标准相结合。我们使用 Kappa 统计量评估方法之间的一致性,并用 Kaplan-Meier 生存曲线和 Cox 比例风险模型评估死亡率。
与标准化病理复查组织学类型相比,各方法之间的一致性较高(历史方法为 kappa=0.892,IHC 整合组织学类型为 0.849),但 IHC 整合组织学类型确定了更多的低级别浆液性癌和一部分被归类为高级别浆液性癌的子宫内膜样癌(n=25)。在不同的方法中,没有观察到组织学类型特异性死亡率的显著差异。
我们的发现表明,组织学类型的分配相当一致,无论采用哪种分类方法,但通过使用 2014 年 WHO 标准进行病理复查以及整合 IHC,可以提高一些不太常见的组织学类型的分类准确性。我们还建议采用一种分类方案,将历史数据纳入 2014 年 WHO 类别,以回答组织学类型特异性的研究问题。